Endo Pharmaceuticals Rating Lowered to Hold at TheStreet (ENDP)
“Endo Health Solutions (ENDP) has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.”
,” TheStreet’s analyst commented.
TheStreet has also modified their ratings on a number of other healthcare stocks in the few days. The firm reiterated its buy rating on shares of Allergan. Also, TheStreet upgraded shares of CoreSite Realty Corp from a hold rating to a buy rating.
Endo Pharmaceuticals opened at 31.05 on Monday. Endo Pharmaceuticals has a 1-year low of $25.01 and a 1-year high of $39.29. The stock’s 50-day moving average is currently $29.28. The company’s market cap is $3.503 billion.
ENDP has been the subject of a number of other recent research reports. Analysts at Piper Jaffray downgraded shares of Endo Pharmaceuticals from a neutral rating to an underweight rating in a research note to investors on Monday, February 25th. They now have a $22.00 price target on the stock, down previously from $28.00. Separately, analysts at RBC Capital downgraded shares of Endo Pharmaceuticals from a sector perform rating to an underperform rating in a research note to investors on Thursday, February 7th. They now have a $24.00 price target on the stock, down previously from $25.00. Finally, analysts at Needham & Company reiterated an underperform rating on shares of Endo Pharmaceuticals in a research note to investors on Thursday, January 31st.
Nine research analysts have rated the stock with a buy rating, nine have issued a hold rating, one has assigned an underweight rating, and two have assigned a sell rating to the company’s stock. The company presently has an average rating of overweight and a consensus price target of $33.08.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.